Obagi Medical Products (OMPI)
Obagi Medical Products Revenues: 30.75M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
OMPI Revenues Rankings
| Overall | 28th percentile | 3184 of 4432 |
| Sector | 52nd percentile | 222 of 471 in Healthcare |
| Industry | 74th percentile | 34 of 132 in Biotechnology |
OMPI Revenues Range, Past 5 Years
| Minimum | 22.62M | Mar 2009 |
| Maximum | 30.75M | Mar 2012 |
| Average | 27.30M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these OMPI related companies
OMPI News
Rumors resurfacing that $OMPI is entertaining several offers including a $20+ offer from a major cosmetics company. http://stks.co/3zy4
about 5 days ago by abubnic
about 5 days ago by abubnic
Of Price Targets and Buyout Rumors for $OMPI. (This buyout rumor has been circulating since January). http://stks.co/3ohf
about 17 days ago by abubnic
about 17 days ago by abubnic
Cantor Fitzgerald Maintains a 'Hold' on Medicis (MRX); Looking For The Accretive Transaction
May 14, 9:53AM Street Insider
May 14, 9:53AM Street Insider
Canaccord Genuity Maintains a 'Buy' on Obagi Medical Products (OMPI); Q1 Strong on Easy Comp
May 04, 11:37AM Street Insider
May 04, 11:37AM Street Insider
Needham & Company Maintains a 'Hold' on Obagi Medical Products (OMPI); Strong Start, But Valuation Keeps Us Sidelined
May 04, 9:28AM Street Insider
May 04, 9:28AM Street Insider
For Q2, $OMPI estimates sales range of $29-$30M and earnings on a GAAP basis. Reiterated year's guidance for net sales betw $119-$124M.
about 28 days ago by abubnic
about 28 days ago by abubnic
$OMPI Q1 2012 Sales Rose 16% to a Record $30.8M; Highest Sales Quarter in Company History. http://stks.co/3f3I
about 28 days ago by abubnic
about 28 days ago by abubnic
Listen to $OMPI Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3ezM
about 28 days ago by earningscast
about 28 days ago by earningscast
$OMPI webcast from the Needham health care conference: http://stks.co/3Mkb
about 45 days ago by abubnic
about 45 days ago by abubnic
$OMPI reports 1st quarter earnings on May 3 @ 4:30 pm. Webcast at http://stks.co/3MkE
about 45 days ago by abubnic
about 45 days ago by abubnic
Obagi Medical Products to Report First Quarter 2012 Financial Results and Host a Conference Call on May 3
Apr 11, 5:44PM Business Wire
Apr 11, 5:44PM Business Wire
Watch $OMPI next week. Held up well during sell-off. Included in the Piper Jaffray analyst/industry call scheduled for April 10th at 10 am.
about 56 days ago by abubnic
about 56 days ago by abubnic
$OMPI product line sold through physicians and hospitals. http://stks.co/37Jt
about 64 days ago by abubnic
about 64 days ago by abubnic
$OMPI Baby boomer market: treats adult skin conditions including premature aging, photodamage, hyperpigmentation, acne and rosacea.
about 64 days ago by abubnic
about 64 days ago by abubnic
$OMPI to Present at The 11th Annual Needham Healthcare Conference, Wed Apr 4. http://stks.co/35IM
about 66 days ago by abubnic
about 66 days ago by abubnic
Obagi Medical Products to Present at The 11th Annual Needham Healthcare Conference
Mar 23, 4:05PM Business Wire
Mar 23, 4:05PM Business Wire
Obagi® Medical Products Presents Study Results at American Academy of Dermatology
Mar 20, 9:00AM Business Wire
Mar 20, 9:00AM Business Wire
Cantor increased its price target on $OMPI to $14 after the company reported those stronger than expected Q4 results.
about 83 days ago by abubnic
about 83 days ago by abubnic
Canaccord Genuity Maintains a 'Buy' on Obagi Medical Products (OMPI); View 2012 as Transitional Year
Mar 09, 10:11AM Street Insider
Mar 09, 10:11AM Street Insider
$OMPI forms bullish "Flag" chart pattern. http://stks.co/2kaj
about 84 days ago by RecogniaEvents
about 84 days ago by RecogniaEvents
Listen to $OMPI Q4 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/2kCt
about 84 days ago by earningscast
about 84 days ago by earningscast
$OMPI Reports Q4 EPS $0.27 vs $0.19 Est; Revenues $30.60M vs $30.64M Est
about 84 days ago by Benzinga
about 84 days ago by Benzinga
Obagi Medical Products Reports Sales and Earnings Growth for the Fourth Quarter and Year Ended December 31, 2011
Mar 08, 4:05PM Business Wire
Mar 08, 4:05PM Business Wire
Obagi Medical Products to Present at The 24th Annual Roth OC Growth Stock Conference
Mar 06, 4:05PM Business Wire
Mar 06, 4:05PM Business Wire
Obagi® Medical Products Wins Best Skincare in the Second Annual NewBeauty Magazine Choice Awards
Jan 04, 4:05PM Business Wire
Jan 04, 4:05PM Business Wire
Discovery Group I Lowers Stake in Obagi Medical Products, Inc. (OMPI) to 7.15%
Nov 15, 4:33PM Street Insider
Nov 15, 4:33PM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| OMPI | 12.39 | -0.20 | -1.59% | 235.31M |
| OMN | 7.19 | +0.07 | +0.98% | 326.02M |
| OMI | 28.46 | +0.30 | +1.07% | 1.790B |
| OMG | 18.21 | -0.49 | -2.62% | 604.57M |
| SHPGY | 84.41 | -1.70 | -1.97% | 16.15B |
| SHP | 6.43 | +0.05 | +0.78% | 119.11M |
| SHOR | 4.19 | +0.17 | +4.23% | 193.64M |
| SHOO | 40.48 | -0.09 | -0.22% | 1.785B |
| SHO | 10.00 | +0.20 | +1.99% | 1.168B |
| SHLO | 10.10 | +0.26 | +2.64% | 165.71M |
